Barclays’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Barclays’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-20,000	Closed	-$385K	–	7021
2017 Q1	$385K	Hold	20,000	–	–	﹤0.01%	3667
2016 Q4	$308K	Sell	20,000 -30,000	-60%	-$389K	﹤0.01%	3816
2016 Q3	$651K	Hold	50,000	–	–	﹤0.01%	3013
2016 Q2	$696K	Buy	+50,000	New	+$736K	﹤0.01%	2920

Other funds holding PRTK

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FIG

Fortress Investment Group New York $394M AUM 22.99% 1-Year Est. Return

Barclays's PRTK Position: Q2 2022 in Review

Barclays sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q2 2022, closing a stake of 7,952 shares — an estimated $24K sold.

Barclays first reported a position in PRTK in Q2 2013 and held it in 27 quarters. The position peaked at $486K in Q1 2021. 84 funds tracked by Wall St. Rank hold PRTK as of Q2 2022.

Barclays reported no remaining Paratek Pharmaceuticals, Inc. position as of Q2 2022 after selling out during the quarter.
Barclays sold 7,952 Paratek Pharmaceuticals, Inc. shares in Q2 2022, an estimated $24K.
Barclays first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2013 and held it in 27 quarters.
Barclays's Paratek Pharmaceuticals, Inc. position peaked at $486K in Q1 2021.
84 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q2 2022.

Based on Barclays's 13F filing for Q2 2022, filed 12 Aug 2022.